Current Location:home > Browse

1. chinaXiv:202002.00079 [pdf]

基于移动平均预测限预判新型冠状病毒感染疫情趋势与适时风险分级

何豪; 何韵婷; 翟晶; 王筱金; 王炳顺
Subjects: Medicine, Pharmacy >> Preventive Medicine and Hygienics

目的 建立一种数据驱动的实用方法预测突发全新传染性疾病的疫情趋势,通过动态预判疫情风险与分级为防控策略提供量化依据。方法 在移动平均法的基础上予以改进,提出一种移动平均预测限(Moving Average Prediction Limits, MAPL)方法,采用既往重症急性呼吸综合征(Severe Acute Respiratory Syndrome,SARS)疫情数据验证MAPL方法对疫情趋势和风险预判的实用性。追踪本次新型冠状病毒(COVID-19)感染疫情从2020年1月16日起的官方公布数据,采用MAPL方法预判疫情变动趋势与疫区适时风险分级。 结果 基于MAPL方法分析显示,2020年2月初全国COVID-19感染疫情达到峰值。经过前期积极防控,2月中旬起全国疫情整体呈下降趋势。到2月下旬各地疫情有明显的区域性差异。与湖北地区相比,非湖北地区新增病例数下降速度快且未来疫情加重的风险相对较小。在几个重要的疫情输入省份,新增确诊病例数和可疑病例数的发展趋势一致,但消减速度在各省份间存在差异。 结论 MAPL方法可以辅助判断疫情趋势并适时预判风险分级,各疫情输入区可结合当地实际与疫情风险分级规划落实差异化精准防控策略。

submitted time 2020-02-28 Hits28084Downloads4404 Comment 0

2. chinaXiv:202002.00070 [pdf]

Towards an effective mRNA vaccine against 2019-nCoV: demonstration of virus-like particles expressed from a modified mRNA cocktail

Xia, Jia; Lu, Guoliang; Lu, Jing; Zhang, Jiahui; Feng, Lin; Wang, Bing; Yu, Hang; Xu, Yingjie; Lin, Jinzhong
Subjects: Biology >> Virology

Frequent outbreaks of coronavirus make the development of an effective vaccine imperative. Recently, vaccines based on in-vitro transcribed messenger RNA (mRNA) have shown great potential. The streamlined manufacturing of mRNA molecules, combined with the superior flexibility in the antigen screening, greatly accelerates the development process. When using an mRNA platform to develop a vaccine, initial antigen choice plays a crucial role in determining the final efficacy and safety of the vaccine. Furthermore, mRNA sequences that encode antigens require extensive optimization to ensure highly efficient and sustained expression. Our ongoing efforts to develop an effective mRNA vaccine against 2019-nCoV place emphasis on the virus-like particles (VLPs) as the presenting antigen. At the same time, our second fast track uses mRNA to express the receptor-binding domain of the spike protein(S-RBD). After extensive optimization, an mRNA cocktail containing three genes is able to produce 2019-nCoV virus-like particles highly similar to the native 2019-nCoV. Meanwhile, an mRNA vaccine candidate expressing S-RBD is being tested in mice for its immunogenicity. We will next compare both the efficacy and the safety of the two mRNA vaccines based on S-RBD and VLPs, respectively.

submitted time 2020-02-25 Hits15891Downloads3369 Comment 0

3. chinaXiv:201605.01497 [pdf]

The hepatitis C virus protein NS3 suppresses TNF-alpha-stimulated activation of NF-kappa B by targeting LUBAC

Chen, Yongzhi; He, Liang; Peng, Yanan; Shi, Xiaodong; Cheng, Genhong; Deng, Hongyu; Chen, Yongzhi; He, Liang; Peng, Yanan; Chen, Jizheng; Chen, Xinwen; Zhong, Jin; Cheng, Genhong;
Subjects: Biology >> Biophysics >> Biochemistry & Molecular Biology

The transcription factor nuclear factor kB (NF-kappa B) is crucial for innate immune defense against viral infections, and its activation requires the ubiquitylation of upstream proteins, including the adaptor protein NEMO (NF-kappa B essential modulator). Many infectious pathogens, including hepatitis C virus (HCV), inhibit NF-kappa B signaling in host cells, which promotes pathogen survival. Frequently, HCV-infected individuals develop a chronic infection, which suggests that HCV can subvert host antiviral responses. We found that HCV infection and replication inhibited the activation of NF-kappa B by the inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha), which was mediated by the viral protein NS3 and, to a lesser extent, NS5B. NS3 directly interacted with linear ubiquitin chain assembly complex (LUBAC), competed with NEMO for binding to LUBAC, and inhibited the LUBAC-mediated linear ubiquitylation of NEMO and the subsequent activation of NF-kappa B. Together, our results highlight an immune evasion strategy adopted by HCV to modulate host antiviral responses and enhance virus survival and persistence.

submitted time 2016-05-12 Hits1950Downloads1105 Comment 0

  [1 Pages/ 3 Totals]